Welcome to our dedicated page for Estrella Immunopharma news (Ticker: ESLA), a resource for investors and traders seeking the latest updates and insights on Estrella Immunopharma stock.
Estrella Immunopharma, Inc. develops clinical-stage ARTEMIS T-cell therapies for cancer and autoimmune diseases. Company updates center on its CD19-targeted lead candidate EB103, the CD19/CD22-targeted EB104 program, and STARLIGHT-1 clinical disclosures in B-cell non-Hodgkin lymphoma and other B-cell malignancy settings.
Recurring news also covers conference presentations, clinical data releases, financing transactions, analyst coverage, Nasdaq listing matters, and governance developments. Estrella's public securities include Nasdaq-listed common stock under ESLA and warrants under ESLAW.
Estrella Immunopharma (NASDAQ: ESLA) has activated University Hospitals Cleveland Medical Center as the fourth clinical site for its ongoing Phase I/II STARLIGHT-1 trial of EB103, a CD19-redirected ARTEMIS T-cell therapy for adults with relapsed or refractory B-cell non-Hodgkin’s lymphoma.
The UH Cleveland Medical Center site, affiliated with Case Western Reserve University School of Medicine, is expected to begin screening and enrolling patients after completing site initiation activities. The expansion phase is a multi-center, open-label study evaluating the safety and efficacy of EB103 at the recommended Phase II dose and is expected to inform Estrella’s pivotal trial strategy. Active sites now include UC Davis Comprehensive Cancer Center, Baylor Scott & White Research Institute, Oregon Health & Science University, and UH Cleveland Medical Center. Trial details are listed under NCT06343311 on ClinicalTrials.gov.
Estrella Immunopharma (NASDAQ: ESLA) has activated Oregon Health & Science University in Portland as the third clinical site for its ongoing STARLIGHT-1 Phase I/II trial of EB103, a CD19-redirected ARTEMIS T-cell therapy for relapsed or refractory B-cell non-Hodgkin’s lymphoma.
The new site has begun screening and enrolling adult patients (≥18 years). The expansion phase is a multi-center, open-label study assessing the safety and efficacy of EB103 at the recommended Phase II dose. According to Estrella Immunopharma, data from this expansion cohort will guide the pivotal trial strategy. Active STARLIGHT-1 sites now include UC Davis Comprehensive Cancer Center, Baylor Scott & White Research Institute, and Oregon Health & Science University. Trial details are listed under NCT06343311 on ClinicalTrials.gov.
Estrella Immunopharma (NASDAQ: ESLA) announced activation of Baylor Scott & White Research Institute in Dallas, Texas as the second clinical site for its ongoing Phase I/II STARLIGHT-1 trial of EB103, a CD19-redirected ARTEMIS T‑cell therapy for relapsed or refractory B‑cell non-Hodgkin’s lymphoma.
According to Estrella, Baylor Scott & White Research Institute has begun screening and enrolling patients. The expansion phase of STARLIGHT-1 is a multi-center, open-label study evaluating the safety and efficacy of EB103 at the recommended Phase II dose in adults (≥18 years) with R/R B‑cell NHL. Data from this expansion cohort are expected to inform the pivotal trial strategy for EB103. As of the announcement date, active sites are UC Davis Comprehensive Cancer Center and Baylor Scott & White Research Institute. Trial details are listed on ClinicalTrials.gov under identifier NCT06343311.
Estrella Immunopharma (NASDAQ: ESLA) announced that the first patient has been successfully dosed in the dose-expansion phase of the ongoing STARLIGHT-1 Phase I/II trial of EB103, a CD19-redirected ARTEMIS T-cell therapy for relapsed/refractory B-cell non-Hodgkin’s lymphoma.
The expansion phase follows dose-escalation data in which, at a 6-month assessment of evaluable Phase I patients without CNS involvement, all patients who achieved a complete response remained in complete response. The multi-center, open-label expansion will evaluate safety and efficacy of EB103 at the recommended Phase II dose in adults with R/R B-cell NHL and will inform the pivotal trial strategy. Active sites include UC Davis Comprehensive Cancer Center and Baylor Scott & White Research Institute, with details listed under NCT06343311 on clinicaltrials.gov.
Estrella Immunopharma (NASDAQ: ESLA) said its CEO and CFO will attend one-on-one investor meetings at the D. Boral Capital 2026 Global Conference on May 7, 2026 at The Plaza Hotel, New York.
The participation offers direct meetings with institutional investors and strategic partners; investors should contact their D. Boral Capital representative to schedule.
Estrella Immunopharma (NASDAQ: ESLA) received initiating coverage from Zacks Small-Cap Research on March 23, 2026, with a $12.00 per share valuation. Zacks highlighted the differentiated ARTEMIS T-cell platform and encouraging Phase I STARLIGHT-1 data for EB103, including a 100% CR at Month 1 in the high-dose cohort (5 evaluable patients) and no Grade 3+ CRS reported.
The report notes favorable safety signals, heavily pretreated/high-risk patient enrollment, CR durations of 3–18 months to date, and that the valuation reflects Zacks SCR’s independent probability-adjusted DCF analysis.
Estrella Immunopharma (Nasdaq: ESLA) presented updated STARLIGHT-1 Phase I data showing promising clinical activity for EB103, a CD19-redirected ARTEMIS T-cell therapy, in aggressive B-cell non-Hodgkin lymphoma.
Key highlights: 100% complete response (CR) in the high-dose cohort at Month 1 (all CRs remain through data cutoff), response durations of 3–18 months with median DOCR not yet reached, one complete responder with PCNSL, and no treatment-related serious adverse events reported in the nine-patient cohort.
Estrella Immunopharma (Nasdaq: ESLA) announced a late-breaking oral presentation of Phase 1 STARLIGHT-1 data for EB103 at the 2026 ASTCT & CIBMTR Tandem Meetings. The presentation (Final Paper LBA-1, Abstract 29644) is scheduled for Feb 7, 2026, 3:15 p.m. MST and the abstract will be posted Feb 4, 2026 at 12:00 a.m. CT.
Presenting author: Naseem Esteghamat, MD MS. The study evaluates CD19-redirected ARTEMIS T cells in aggressive B-cell non-Hodgkin lymphoma.
Estrella Immunopharma (NASDAQ: ESLA) closed a registered direct offering and a concurrent private placement on January 6, 2026, raising approximately $8.0 million aggregate gross proceeds.
The company issued 4,063,290 common shares and 1,000,000 pre-funded warrants; it also issued common warrants to purchase up to 7,594,935 shares. The combined price per share with warrant was $1.58 (pre-funded $1.57999). Pre-funded warrants carry a $0.00001 exercise price and no expiration; common warrants have a $1.39 strike and five-year term. Net proceeds are planned for general corporate purposes and to advance the lead program, EB103, through Phase II.
Estrella Immunopharma (NASDAQ: ESLA) announced definitive agreements for a registered direct offering and a concurrent private placement, together expected to raise approximately $8.0 million. The transaction, priced at-the-market under Nasdaq rules, consists of 5,063,290 Common Units (or Pre-Funded Units) and a total of 7,594,935 PIPE Common Warrants, each exercisable at $1.39. The offering price per Common Unit is $1.58 (Pre-Funded Unit: $1.5799). The Pre-Funded Warrants are immediately exercisable. Closing is expected on or about January 6, 2026. Net proceeds will be used for general corporate purposes and working capital; Aegis Capital is sole placement agent.